Communication Address:
Solara Active Pharma Sciences Limited
2nd Floor, Admin Block
27, Vandaloor Kelambakkam Road,
Keelakottaiyur Village, Melakottaiyur (Post)
Chennai – 600 127, India
Tel: +91 44 43446700
Fax: +91 44 47406190
E-mail: investors@solara.co.in
www.solara.co.in

February 13, 2023

The BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai - 400 001

Scrip Code: 541540

The National Stock Exchange of India Limited
Exchange Plaza Bandra Kurla Complex Sandra (E)
Mumbai - 400 051

Scrip Code: SOLARA

Dear Sir/ Madam,

Sub: Completion of the EU-GMP inspection at the Cuddalore facility of the Company

We would like to update you that **Solara Active Pharma Sciences Limited** (Solara) has successfully completed the **EU GMP Inspection** carried out jointly by the **"State Institute for Drug Control (SUKL), Ministry of Health of the Czech Republic"** and **"National Authority of Medicines and Health Products (INFARMED), Portugal"** at its Cuddalore facility (Tamil Nadu) between 07 to 09, February 2023.

At the end of the inspection, it is concluded that the Quality Systems followed at our Cuddalore site is **Compliant to the EU GMP Standards.**

The Cuddalore API site is a multi-product facility, caters wide range of APIs to various Regulated Markets across the globe, including U.S., Europe, Japan and other markets.

This is for your information and records.

Thanking you,
Yours Truly,

For Solara Active Pharma Sciences Limited

SUDDAPALLI MURALIKRISHNA
Digitally signed by SUDDAPALLI MURALIKRISHNA
Date: 2023.02.13 10:35:47 +05'30'

S. Murali Krishna
Company Secretary

SOLARA
Active Pharma Sciences

Press Release

Solara's Cuddalore facility successfully completes EU GMP Inspection

Bengaluru, India – February 13, 2023: Solara Active Pharma Sciences Ltd (Solara) (NSE: SOLARA; BSE: 541540), a leading Active Pharmaceutical Ingredient / CRAMS company, today announced the successful completion EU-GMP Inspection, carried out jointly by the **"State Institute for Drug Control (SUKL), Ministry of Health of the Czech Republic"** and **"National Authority of Medicines and Health Products (INFARMED), Portugal"** from **07th to 09th February 2023,** at the multi-product manufacturing facility at Cuddalore.

At the end of the inspection, it is concluded that the Quality Systems followed at our Cuddalore site is **Compliant to the EU GMP Standards.**

This Cuddalore facility has also successfully completed the inspection carried out by the World Health Organization (WHO) between January 23 - 26, 2023.

Jitesh Devendra, Managing Director, commented, *We are happy with the successful outcome* of *two consecutive regulatory inspections, EU-GMP and WHO-GMP inspections at our Cuddalore facility. The result of these inspections demonstrates our commitment to regulatory excellence at our global manufacturing sites. We stay committed to high degree of compliance across Solara's manufacturing network.*

The Cuddalore multi-product API manufacturing facility was established in the year 1991 and is equipped with appropriate infrastructure to include several independent production blocks and related packaging sections. This site is inspected by various Regulatory Authorities including US FDA, MHRA, EDQM, WHO, PMDA, TGA, KFDA, and COFEPRIS.

About Solara

Solara Active Pharma Sciences Ltd (BSE-541540, NSE-SOLARA), headquartered in Bengaluru, India, offers a basket of diversified, high-value Commercial APIs and Contract manufacturing services in over 75 countries. It has a manufacturing base comprising six globally compliant API facilities, with approvals including the USFDA, EU GMP, and PMDA in Japan.

Investor / Analyst contact

Abhishek Singhal
✉ abhishek.singhal@solara.co.in
✆ +91 99877 66968

Statutory and corporate affairs

Murali Krishna S
Raghavan. V
✉ investors@solara.co.in